Atlas Capital Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $142K | Sell |
564
-5,739
| -91% | -$1.23M | 0.02% | 540 |
|
|
2026
Q1 | $1.37M | Buy |
6,303
+39
| +0.6% | +$8.65K | 0.16% | 121 |
|
|
2025
Q4 | $1.43M | Buy |
+6,264
| New | +$1.43M | 0.16% | 118 |
|
|
2025
Q2 | $1.16M | Sell |
6,248
-858
| -12% | -$159K | 0.14% | 129 |
|
|
2025
Q1 | $1.49M | Hold |
7,106
| – | – | 0.19% | 101 |
|
|
2024
Q4 | $1.26M | Buy |
7,106
+5,700
| +405% | +$1.05M | 0.16% | 110 |
|
|
2024
Q3 | $278K | Sell |
1,406
-5,700
| -80% | -$1.06M | 0.04% | 322 |
|
|
2024
Q2 | $1.22M | Buy |
7,106
+5,700
| +405% | +$944K | 0.16% | 107 |
|
|
2024
Q1 | $256K | Sell |
1,406
-5,700
| -80% | -$982K | 0.04% | 330 |
|
|
2023
Q4 | $1.1M | Hold |
7,106
| – | – | 0.16% | 105 |
|
|
2023
Q3 | $1.06M | Sell |
7,106
-52
| -0.7% | -$7.63K | 0.17% | 100 |
|
|
2023
Q2 | $964K | Sell |
7,158
-113
| -2% | -$16.6K | 0.15% | 112 |
|
|
2023
Q1 | $1.16M | Hold |
7,271
| – | – | 0.18% | 92 |
|
|
2022
Q4 | $1.18M | Sell |
7,271
-13
| -0.2% | -$1.99K | 0.2% | 99 |
|
|
2022
Q3 | $978K | Sell |
7,284
-170
| -2% | -$24.4K | 0.18% | 104 |
|
|
2022
Q2 | $1.14M | Buy |
7,454
+476
| +7% | +$72.7K | 0.19% | 98 |
|
|
2022
Q1 | $1.13M | Sell |
6,978
-28
| -0.4% | -$4.07K | 0.18% | 104 |
|
|
2021
Q4 | $949K | Sell |
7,006
-1,473
| -17% | -$174K | 0.14% | 123 |
|
|
2021
Q3 | $915K | Buy |
8,479
+1,779
| +27% | +$203K | 0.15% | 119 |
|
|
2021
Q2 | $755K | Buy |
6,700
+70
| +1% | +$7.88K | 0.13% | 147 |
|
|
2021
Q1 | $717K | Buy |
6,630
+170
| +3% | +$18.2K | 0.14% | 146 |
|
|
2020
Q4 | $692K | Sell |
6,460
-803
| -11% | -$77.2K | 0.15% | 138 |
|
|
2020
Q3 | $636K | Sell |
7,263
-197
| -3% | -$18.5K | 0.15% | 149 |
|
|
2020
Q2 | $732K | Buy |
7,460
+1,460
| +24% | +$129K | 0.17% | 130 |
|
|
2020
Q1 | $457K | Hold |
6,000
| – | – | 0.14% | 164 |
|
|
2019
Q4 | $531K | Hold |
6,000
| – | – | 0.13% | 188 |
|
|
2019
Q3 | $454K | Sell |
6,000
-229
| -4% | -$15.7K | 0.14% | 195 |
|
|
2019
Q2 | $453K | Hold |
6,229
| – | – | 0.15% | 181 |
|
|
2019
Q1 | $502K | Sell |
6,229
-3,402
| -35% | -$278K | 0.18% | 151 |
|
|
2018
Q4 | $888K | Sell |
9,631
-5,380
| -36% | -$473K | 0.36% | 76 |
|
|
2018
Q3 | $1.44M | Sell |
15,011
-2,385
| -14% | -$226K | 0.48% | 52 |
|
|
2018
Q2 | $1.66M | Buy |
17,396
+2,237
| +15% | +$218K | 0.59% | 37 |
|
|
2018
Q1 | $1.43M | Buy |
+15,159
| New | +$1.67M | 0.44% | 56 |
|
Other funds holding ABBV
Atlas Capital Advisors's ABBV Position: Q2 2026 in Review
Atlas Capital Advisors reduced its AbbVie (ABBV) stake by 91% in Q2 2026, selling an estimated $1.23M and leaving 564 shares worth $142K. The position accounts for 0.02% of the portfolio, ranked #540.
Atlas Capital Advisors first reported a position in ABBV in Q1 2018 and has held it in 33 quarters since. The position peaked at $1.66M in Q2 2018. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Atlas Capital Advisors held 564 shares of AbbVie worth $142K as of Q2 2026.
- Atlas Capital Advisors sold 5,739 AbbVie shares in Q2 2026, an estimated $1.23M.
- AbbVie made up 0.02% of Atlas Capital Advisors's portfolio in Q2 2026, its #540 holding.
- Atlas Capital Advisors first reported a position in AbbVie in Q1 2018 and has held it in 33 quarters since.
- Atlas Capital Advisors's AbbVie position peaked at $1.66M in Q2 2018.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.